JP2023550419A5 - - Google Patents
Info
- Publication number
- JP2023550419A5 JP2023550419A5 JP2023530164A JP2023530164A JP2023550419A5 JP 2023550419 A5 JP2023550419 A5 JP 2023550419A5 JP 2023530164 A JP2023530164 A JP 2023530164A JP 2023530164 A JP2023530164 A JP 2023530164A JP 2023550419 A5 JP2023550419 A5 JP 2023550419A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- seq
- chain variable
- group
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2020/129918 | 2020-11-18 | ||
| CN2020129918 | 2020-11-18 | ||
| CNPCT/CN2021/073341 | 2021-01-22 | ||
| CN2021073341 | 2021-01-22 | ||
| PCT/CN2021/131389 WO2022105817A1 (en) | 2020-11-18 | 2021-11-18 | Bi-functional molecules |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023550419A JP2023550419A (ja) | 2023-12-01 |
| JP2023550419A5 true JP2023550419A5 (enExample) | 2024-11-26 |
Family
ID=81708373
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023530164A Pending JP2023550419A (ja) | 2020-11-18 | 2021-11-18 | 二機能性分子 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240043566A1 (enExample) |
| EP (1) | EP4247424A4 (enExample) |
| JP (1) | JP2023550419A (enExample) |
| KR (1) | KR20230110546A (enExample) |
| CN (1) | CN116390948A (enExample) |
| AU (1) | AU2021383879A1 (enExample) |
| CA (1) | CA3201518A1 (enExample) |
| TW (1) | TW202235104A (enExample) |
| WO (1) | WO2022105817A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3095675A1 (en) | 2020-10-07 | 2022-04-07 | Xbiotech Inc. | True human antibody specific for interleukin 1 alpha (il-1a) |
| CA3095676A1 (en) | 2020-10-07 | 2022-04-07 | Xbiotech Inc. | True human antibody specific for interleukin 1 alpha (il-1a) |
| CA3095740A1 (en) | 2020-10-07 | 2022-04-07 | Xbiotech Inc. | True human antibody specific for interleukin alpha (il-1a) |
| CA3095679A1 (en) * | 2020-10-07 | 2022-04-07 | Xbiotech Inc. | True human antibody specific for interleuken 1 alpha (il-1a) |
| CN119213034A (zh) * | 2022-05-17 | 2024-12-27 | 苏州创胜医药集团有限公司 | 双功能蛋白质及其制剂和用途 |
| AU2022481989A1 (en) * | 2022-10-13 | 2025-05-22 | Dartsbio Pharmaceuticals Ltd. | B7h3/pdl1 bispecific antibody, and pharmaceutical composition comprising same and use thereof |
| GB202402046D0 (en) * | 2024-02-14 | 2024-03-27 | Bivictrix Ltd | Therapeutic antibodies |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1212422B1 (en) * | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| CA2672229A1 (en) * | 2006-12-14 | 2008-06-19 | Actogenix N.V. | Delivery of binding molecules to induce immunomodulation |
| US20130195868A1 (en) * | 2010-06-24 | 2013-08-01 | Eleven Biotherapeutics, Inc. | Treating surface of the eye disorders |
| US9682143B2 (en) * | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| EP2931750B8 (en) * | 2012-12-17 | 2021-11-03 | Cell Medica Inc. | Antibodies against il-1 beta |
| JP2016513098A (ja) * | 2013-02-07 | 2016-05-12 | イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． | 癌の標的治療用抗体と抱合した極めて強力なプロドラック形態の２−ピロリノドキソルビシン（ｐ２ｐｄｏｘ） |
| ES2986067T3 (es) * | 2015-12-17 | 2024-11-08 | Novartis Ag | Moléculas de anticuerpos frente a PD-1 y usos de las mismas |
| CA3007135A1 (en) * | 2016-03-23 | 2017-09-28 | Mabspace Biosciences (Suzhou) Co., Ltd | Novel anti-pd-l1 antibodies |
| WO2018014260A1 (en) * | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
| CN108220228A (zh) * | 2016-12-09 | 2018-06-29 | 上海迈泰君奥生物技术有限公司 | 无血清细胞培养基及高效表达重组蛋白质的方法 |
| AU2018266103B2 (en) * | 2017-05-09 | 2024-06-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Combination PDL1 and TGF-beta blockade in patients with HPV+ malignancies |
| US11718673B2 (en) * | 2019-04-01 | 2023-08-08 | Immetas Therapeutics, Inc. | Bispecific binding molecules that target the tumor microenvironment and an immune checkpoint protein |
| CN111763261B (zh) * | 2019-04-02 | 2022-08-09 | 杭州尚健生物技术有限公司 | 一种融合蛋白及其用途 |
-
2021
- 2021-11-18 WO PCT/CN2021/131389 patent/WO2022105817A1/en not_active Ceased
- 2021-11-18 AU AU2021383879A patent/AU2021383879A1/en active Pending
- 2021-11-18 TW TW110143071A patent/TW202235104A/zh unknown
- 2021-11-18 EP EP21893964.3A patent/EP4247424A4/en active Pending
- 2021-11-18 CA CA3201518A patent/CA3201518A1/en active Pending
- 2021-11-18 KR KR1020237020099A patent/KR20230110546A/ko active Pending
- 2021-11-18 US US18/253,398 patent/US20240043566A1/en active Pending
- 2021-11-18 CN CN202180072768.8A patent/CN116390948A/zh active Pending
- 2021-11-18 JP JP2023530164A patent/JP2023550419A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023550419A5 (enExample) | ||
| JP7773528B2 (ja) | 抗ｃｄ２８組成物 | |
| JP7846668B2 (ja) | リガンド－受容体対及び生物学的に機能的なタンパク質を含む融合タンパク質 | |
| JP6622396B2 (ja) | 多重特異性抗体プラットフォームおよびその関連方法 | |
| JP7746258B2 (ja) | 特性が改善されたｐｄ－１標的化ｉｌ－１５／ｉｌ－１５ｒαｆｃ融合タンパク質 | |
| WO2020023702A1 (en) | Novel il-21 prodrugs and methods of use thereof | |
| JP2021521275A5 (enExample) | ||
| JP2021525082A5 (enExample) | ||
| AU2019359475A1 (en) | PD-1 targeted IL-15/IL-15Ralpha Fc fusion proteins and uses in combination therapies thereof | |
| JP7737306B2 (ja) | Ｔ細胞に結合する多機能性分子および自己免疫障害を処置するためのその使用 | |
| JP2021520829A (ja) | ＩＬ−１５／ＩＬ−１５ＲＡ Ｆｃ融合タンパク質およびＴＩＭ−３抗原結合ドメインを含む、ＴＩＭ−３標的化ヘテロ二量体融合タンパク質 | |
| JP2021521779A (ja) | ＩＬ−１５／ＩＬ−１５ＲＡ Ｆｃ融合タンパク質およびＬＡＧ−３抗原結合ドメインを含む、ＬＡＧ−３を標的とするヘテロ二量体融合タンパク質 | |
| JP2023159379A (ja) | Ｐｄ－１とｖｅｇｆを標的とした四価二重特異性抗体、その製造方法および用途 | |
| US20240043566A1 (en) | Bi-functional molecules | |
| US20220089722A1 (en) | Heterodimeric fusion protein | |
| JP2023543896A5 (enExample) | ||
| CN119365490A (zh) | 结合pd-l1、pd-l2和/或cd28的抗体 | |
| JP2025503480A5 (enExample) | ||
| WO2025201240A1 (en) | Antibodies targeting cd3, cd28, and pd-l1 and uses thereof | |
| US20250282874A1 (en) | Bifunctional protein, and preparation thereof and use thereof | |
| HK40103881A (zh) | Pd-1靶向il-2变体免疫缀合物和fap/4-1bb结合分子的组合疗法 | |
| RU2024117654A (ru) | Антитела к b7-h4 и слитые белки антитело к b7-h4/il-15 | |
| CN116547306A (zh) | 抗cd28和/或抗b7h3组合物 | |
| TH2101001840A (th) | แอนติบอดีสารต้าน hla-g, องค์ประกอบซึ่งประกอบรวมด้วยแอนติบอดีสารต้าน hla-g และวิธีของการใช้แอนติบอดีสารต้าน hla-g | |
| HK40094278B (zh) | 包含配体-受体对和生物功能蛋白的融合蛋白 |